UK Companies House feature
NICOBRAND LIMITED
Cash
£2M
-14.6% vs 2023
Net assets
£41M
+79.4% vs 2023
Employees
65
+32.7% vs 2023
Profit before tax
£27M
+161% vs 2023
Profile
- Company number
- NI033276
- Status
- Active
- Incorporation
- 1997-11-19
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Net assets
7-year trend · vs UK Healthcare median
Accounts
7-year trend · latest 2024-12-31
| Metric | Trend | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | — | |
| Operating profit | — | — | — | — | — | — | — | |
| Profit before tax | — | — | — | — | — | £10,458,342 | £27,293,366 | |
| Net profit | — | — | — | — | — | £7,926,711 | £20,493,757 | |
| Cash | — | — | — | — | — | £2,919,085 | £2,491,541 | |
| Total assets less current liabilities | — | — | — | — | — | £22,963,063 | £41,198,402 | |
| Net assets | — | — | — | — | — | £22,623,971 | £40,593,678 | |
| Equity | — | — | — | £14,402,974 | £16,429,460 | £22,623,971 | £40,593,678 | |
| Average employees | — | — | — | — | — | 49 | 65 | |
| Wages | — | — | — | — | — | £1,852,964 | £2,431,177 |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Moore (N.I.) LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”
Significant events
- “During 2024 the business continued to extend our product offerings within the Next Generation Products category. The directors consider the results for the period to be satisfactory given the trading environment. The company will continue to seek every opportunity to increase profitable turnover.”
- “The KPI's which are most suitable for the Company are sales growth, £66.3m in 2024 (£28.7m in 2023), and achieved margins with gross profits & net profits of £31.5m & £27.3m respectively in 2024 (£13.0m & £10.5m in 2023).”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BOYD, Helen Doreen | Secretary | 2016-01-19 | — | — |
| BOYD, Helen Doreen | Director | 2011-08-26 | May 1968 | British |
| MCQUILLAN, Mark | Director | 2011-08-26 | Aug 1976 | Irish |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BUCHEN, David | Secretary | 1997-11-19 | 2016-01-19 |
| PINSENT MASONS SECRETARIAL LIMITED | Corporate Secretary | 2017-03-13 | 2017-03-13 |
| BISARO, Paul Mino | Director | 2008-01-01 | 2011-08-30 |
| BUCHEN, David Adam | Director | 2002-05-10 | 2016-01-19 |
| CHAO (DR), Allen | Director | 1998-07-10 | 2008-01-01 |
| COOPER, Dean Michael | Director | 2018-07-12 | 2019-07-30 |
| HUMPHREY, John Alexander | Director | 1997-11-19 | 2011-08-30 |
| LAWRENCE, David | Director | 1998-07-10 | 2002-08-16 |
| MORROD, Ronald Jeffrey | Director | 2011-09-06 | 2014-03-31 |
| STEWART, Robert | Director | 2011-08-30 | 2016-08-02 |
| WILLIAMS, Robert | Director | 2016-08-02 | 2018-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Contraf -Nicotex-Tobacco Gmbh | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-07-01 | Active |
| Teva Pharmaceutical Industries Limited | Corporate entity | Shares 75–100%, voting-rights-75-to-100-percent-as-firm, Appoints directors | 2016-08-02 | Ceased 2019-06-28 |
Filing timeline
Last 20 of 114 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-12-12 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-07-03 | AA | accounts | accounts with accounts type full |
| 2024-11-21 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-05-09 | AA | accounts | accounts with accounts type full |
| 2023-12-06 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-06-01 | AA | accounts | accounts with accounts type full |
| 2022-11-23 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-04-12 | AA | accounts | accounts with accounts type full |
| 2022-01-06 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-03-08 | AA | accounts | accounts with accounts type full |
| 2020-11-17 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2020-03-02 | AA | accounts | accounts with accounts type full |
| 2019-11-27 | CS01 | confirmation-statement | confirmation statement with updates |
| 2019-11-20 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2019-09-09 | CH01 | officers | change person director company with change date |
| 2019-07-30 | TM01 | officers | termination director company with name termination date |
| 2019-07-29 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2019-07-29 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2019-03-15 | AA | accounts | accounts with accounts type full |
| 2018-12-03 | CS01 | confirmation-statement | confirmation statement with updates |
Credit score
Altman Z″ (private-firm) · reference 2024-12-31
15.50
SAFE
Altman Z″
- Working capital / Total assets 0.721 × 6.56 = +4.73
- Retained earnings / Total assets 0.000 × 3.26 = +0.00
- EBIT / Total assets 0.584 × 6.72 = +3.93
- Book equity / Total liabilities 6.524 × 1.05 = +6.85
Bands: > 2.6 safe · 1.1–2.6 grey · < 1.1 distress. Z″ is a public-formula baseline, not a substitute for adverse-data signals (CCJs, charges, gazette notices) — those land in a later pass.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory